

DDN SYMPOSIUM

ADVANCES IN IMMUNO-ONCOLOGY

	DAY 1 AUGUST 26th	
TIME (ET)	SESSION	
11:00 AM	The next generation of precision oncology: Integrating personalized medicine to improve cancer outcomes Nathan Goodyear, PhD, Williams Cancer Institute	
11:50 AM	From biospecimens to patient-derived models for immuno-oncology research Bradley N. Mills, PhD, University of Rochester Medical Center	
12:35 PM	Identifying and characterizing tumor-reactive TIL in the tumor microenvironment Zhen Zeng, PhD, Johns Hopkins Medicine	
1:25 PM	Engineering mechanistic clarity: how antibody design decisions shape targeted antibody therapies Rebecca Argyros, Bio X Cell	
1:45 PM	Harnessing innate immunity and the ELANE pathway to selectively kill cancer cells and activate anti-tumor immunity Chang Cui, PhD, Onchilles Pharma	
2:35 PM	TBD x	
2:55 PM	Overcoming the bloodstream barrier: systemic delivery of enveloped virotherapies to target metastatic disease Eric Poma, Calidi Biotherapeutics	
	DAY 2 AUGUST 27th	
TIME (ET)	SESSION	
11:00 AM	CD28 T cell engagers in prostate cancer Bilal A. Siddiqui, M.D., MD Anderson Cancer Center	
11:50 AM	Curing myeloma with immune therapy Sagar Lonial, MD, Winship Cancer Institute of Emory University	
12:45 PM	Harnessing B cells and tertiary lymphoid structures for improved immunotherapeutic strategies Tullia C. Bruno, PhD, University of Pittsburgh School of Medicine	
1:45 PM	Building the tumor microenvironment in 3D: multicellular models for developing anti-cancer and immunotherapy approaches Matthieu Spriet, PhD, Inventia Life Science	
2:10 PM	Translating tumor microenvironment biology into a clinically accessible blood-based assay Mirna Jarosz, PhD, LiquidCell Dx	
2:10 PM	TBD x	